Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.…
Imunon, Inc. Q3 2026 Earnings Call Summary
Imunon (NASDAQ: IMNN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 20 employees.
The shares were at 0.5355 USD on 20 November 2026, down 86.6% over 52 weeks. Its 52-week range is 0.4950 USD to 4.380 USD: the price is 87.8% below the high and 8.2% above the low.
Its market capitalisation is 3.47M USD.
Imunon reports return on equity of -205.3% and an operating margin of 0.0%.
Its debt exceeds its cash by 980.91K USD, a debt-to-equity ratio of 0.14. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.